The Future of Alzheimer's Breakthroughs and Challenges PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The Future of Alzheimer's Breakthroughs and Challenges PDF full book. Access full book title The Future of Alzheimer's Breakthroughs and Challenges by United States. Congress. Senate. Special Committee on Aging. Download full books in PDF and EPUB format.
Author: United States. Congress. Senate. Special Committee on Aging
Publisher:
ISBN:
Category : Alzheimer's disease
Languages : en
Pages : 96
Get Book
Book Description
Author: United States. Congress. Senate. Special Committee on Aging
Publisher:
ISBN:
Category : Alzheimer's disease
Languages : en
Pages : 96
Get Book
Book Description
Author: National Academies of Sciences Engineering and Medicine
Publisher:
ISBN: 9780309495035
Category :
Languages : en
Pages :
Get Book
Book Description
As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.
Author: Ahmed Moustafa
Publisher: Academic Press
ISBN: 0128213353
Category : Medical
Languages : en
Pages : 254
Get Book
Book Description
Nearly 44 million people have Alzheimer’s or related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia. First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer’s disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer’s diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer’s disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. Reviews recent developments of cognitive and clinical studies Covers factors underlying the transition from mild cognitive impairment to Alzheimer’s disease Discusses different neural biomarkers underlying the development and treatment of Alzheimer’s disease Provides a comparison of the effectiveness of various types of treatments
Author: Jeffrey Cummings
Publisher: Cambridge University Press
ISBN: 1108838669
Category : Business & Economics
Languages : en
Pages : 575
Get Book
Book Description
Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
Author: Magisetty Obulesu
Publisher: Academic Press
ISBN: 0128167394
Category : Medical
Languages : en
Pages : 80
Get Book
Book Description
Alzheimer’s Disease Theranostics discusses the latest information on recent theranostic avenues for both the diagnosis and treatment of Alzheimer’s patients. It presents the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of existing maneuvers and suggests perspectives to aid in future developments. Despite the difficulty of drug delivery to the brain, there are some nanoparticulate platforms demonstrating promise in treating neurodegenerative disorders such as Alzheimer’s disease. Manifold theranostic maneuvers include antioxidants, natural bioactive compounds, gene therapy, and nanotechnological approaches, all of which are discussed in this important work. Examines various theranostic applications for the diagnosis and treatment of Alzheimer’s disease Features a comprehensive overview of nanoparticle therapeutics in the area and use of antioxidants Assesses the common challenges and lessons learned from blood-brain barrier challenges, viral vector approaches and mitochondria-targeted therapeutics
Author: Karl Herrup
Publisher: MIT Press
ISBN: 0262546019
Category : Health & Fitness
Languages : en
Pages : 269
Get Book
Book Description
An authority on Alzheimer's disease offers a history of past failures and a roadmap that points us in a new direction in our journey to a cure. For decades, some of our best and brightest medical scientists have dedicated themselves to finding a cure for Alzheimer's disease. What happened? Where is the cure? The biggest breakthroughs occurred twenty-five years ago, with little progress since. In How Not to Study a Disease, neurobiologist Karl Herrup explains why the Alzheimer's discoveries of the 1990s didn't bear fruit and maps a direction for future research. Herrup describes the research, explains what's taking so long, and offers an approach for resetting future research. Herrup offers a unique insider's perspective, describing the red flags that science ignored in the rush to find a cure. He is unsparing in calling out the stubbornness, greed, and bad advice that has hamstrung the field, but his final message is a largely optimistic one. Herrup presents a new and sweeping vision of the field that includes a redefinition of the disease and a fresh conceptualization of aging and dementia that asks us to imagine the brain as a series of interconnected "neighborhoods." He calls for changes in virtually every aspect of the Alzheimer's disease research effort, from the drug development process, to the mechanisms of support for basic research, to the often-overlooked role of the scientific media, and more. With How Not to Study a Disease, Herrup provides a roadmap that points us in a new direction in our journey to a cure for Alzheimer's.
Author: Lisa Snyder
Publisher: Sunrise River Press
ISBN: 1934716189
Category : Health & Fitness
Languages : en
Pages : 286
Get Book
Book Description
Speaks directly to the person diagnosed with early-stage Alzheimer's and offers them the information they need to move ahead.
Author: Illana Gozes
Publisher: Academic Press
ISBN: 0128037121
Category : Medical
Languages : en
Pages : 342
Get Book
Book Description
Neuroprotection in Alzheimer’s Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer’s disease will pave the path to better disease management and novel therapeutics. Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development Edited by one of the leading researchers in Alzheimer’s Disease
Author: Daniel Gibbs
Publisher: Cambridge University Press
ISBN: 1009333585
Category : Medical
Languages : en
Pages : 227
Get Book
Book Description
Dr Daniel Gibbs is one of 50 million people worldwide with an Alzheimer's disease diagnosis. Unlike most patients with Alzheimer's, however, Dr Gibbs worked as a neurologist for twenty-five years, caring for patients with the very disease now affecting him. Also unusual is that Dr Gibbs had begun to suspect he had Alzheimer's several years before any official diagnosis could be made. Forewarned by genetic testing showing he carried alleles that increased the risk of developing the disease, he noticed symptoms of mild cognitive impairment long before any tests would have alerted him. In this highly personal account, Dr Gibbs documents the effect his diagnosis has had on his life and explains his advocacy for improving early recognition of Alzheimer's. Weaving clinical knowledge from decades caring for dementia patients with his personal experience of the disease, this is an optimistic tale of one man's journey with early-stage Alzheimer's disease. Soon to be a documentary film on MTV/Paramount +.
Author: Atta-ur-Rahman
Publisher: Elsevier
ISBN: 0128039604
Category : Science
Languages : en
Pages : 784
Get Book
Book Description
Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
